

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1681)

NOTICE OF BOARD MEETING

The board of directors (the “**Board**”) of Consun Pharmaceutical Group Limited (the “**Company**”) hereby announces that a meeting of the Board will be held on Wednesday, 21 August 2019 for the following purposes:

1. To consider and approve the unaudited consolidated financial statements of the Company and its subsidiaries (collectively the “**Group**”) for the 6 months ended 30 June 2019 (the “**Interim Results**”);
2. To consider and approve the draft announcement of the Interim Results of the Group to be published in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited;
3. To consider the recommendation on the payment of an interim dividend, if any; and
4. To consider and approve other matters, if any.

By order of the Board

Consun Pharmaceutical Group Limited

AN Yubao

Chairman

Hong Kong, 22 July 2019

As at the date of this announcement, the Board comprises Mr. AN Yubao, Ms. LI Qian, Professor ZHU Quan and Mr. TANG Ning as executive Directors; Mr. SU Yuanfu, Mr. FENG Zhongshi and Ms. CHEN Yujun as independent non-executive Directors.